

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

HOPEWELL PHARMA VENTURES, INC.,  
Petitioner,

v.

MERCK SERONO SA,  
Patent Owner.

---

Case IPR2023-00481  
Patent 8,377,903

---

**PATENT OWNER'S PRELIMINARY RESPONSE**

**TABLE OF CONTENTS**

I. Introduction..... 1

II. Background..... 4

III. Person Of Ordinary Skill In The Art ..... 6

IV. Claim Construction..... 6

V. Petitioner Is Not Reasonably Likely To Prevail On Ground I ..... 16

    A. Petitioner Fails To Establish That Bodor And Stelmasiak  
        Disclose Or Suggest All Claim Limitations..... 17

        1. Neither Bodor Nor Stelmasiak Discloses Or Suggests  
            The Claimed Weight-Based Oral, Induction Or  
            Maintenance Dosing ..... 17

        2. Neither Bodor Nor Stelmasiak Discloses Or Suggests A  
            Maintenance Period As Claimed ..... 21

    B. Petitioner Has Not Established Any Motivation To Combine  
        Bodor With Stelmasiak To Arrive At The Challenged Claims ..... 29

        1. A POSA Would Not Have Been Motivated To Adopt  
            Weight-Based Dosing ..... 29

        2. A POSA Would Not Have Been Motivated To Combine  
            Bodor With Stelmasiak To Arrive At The Claimed  
            Induction Doses..... 30

3.	A POSA Would Not Have Been Motivated To Re-Treat Patients After Bodor’s 10-Month Cladribine-Free Period.....	37
4.	A POSA Would Not Have Been Motivated To Combine Bodor With Stelmasiak To Arrive At The Claimed 1.7 Mg/Kg Maintenance Dose .....	38
5.	Petitioner’s Routine Optimization Arguments Fail To Explain How A POSA Would Have Been Motivated To Arrive At Claimed Dosing Methods .....	40
C.	Petitioner Has Not Established Any Reasonable Expectation Of Success In Combining Bodor’s Method With Stelmasiak To Arrive At The Challenged Claims .....	45
1.	A POSA Would Not Have Reasonably Expected To Arrive At The Claimed Weight-Based Dosing.....	46
2.	A POSA Would Not Have Reasonably Expected To Arrive At The Claimed 1.7-3.5 Mg/Kg Total Induction Dose By Modifying Bodor’s Method In View Of Stelmasiak .....	46
3.	A POSA Would Not Have Reasonably Expected To Treat RRMS Or Early SPMS Using The Claimed About	

8-10- Or 10-Month Cladribine-Free Period By  
Modifying Bodor’s Method In View Of Stelmasiak .....47

4. A POSA Would Not Have Reasonably Expected To  
Arrive At The Claimed About 1.7 Mg/Kg Maintenance  
Dose By Modifying Bodor’s Method In View Of  
Stelmasiak .....49

5. A POSA Would Not Have Reasonably Expected To  
Arrive At A Safe And Effective Method Of Treating  
RRMS Or Early SPMS As Claimed By Modifying  
Bodor’s Method In View Of Stelmasiak .....50

VI. Objective Indicia Support Non-Obviousness .....52

VII. The Petition Should Be Denied Under 35 U.S.C. § 325(d).....53

A. The Office Already Considered Petitioner’s Alleged Prior  
Art And Arguments .....53

1. Becton Dickinson Factors (a) And (b): Asserted Art  
Was Considered During Examination .....54

2. Becton Dickinson Factor (d): Petitioner’s And The  
Examiner’s Arguments Are Not Materially Different.....55

B. Petitioner Has Not Identified A Material Error By The  
Examiner .....58

1.	Becton Dickinson Factor (c): Asserted Art Was Evaluated During Examination.....	59
2.	Becton Dickinson Factor (e): Petitioner Has Not Identified Material Examiner Error .....	60
3.	Becton Dickinson Factor (f): Additional Evidence Does Not Warrant Reconsideration .....	63
VIII.	Conclusion .....	64

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.